SEP 1 1 1006 E

In re Application : MARK J. MAMULA

Serial No. : 10/613,272 Filed : July 3, 2003

For : INDUCTION OF IMMUNE RESPONSES TO

ISOASPARTYL-MODIFIED ANTIGENS

Examiner : Karen A. Canella

Attorney Docket : 102321-201

Group Art Unit : 1643 Confirmation No. : 4375 Customer No. : 27267

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 07 SEPT 200

Вν

Todd E. Garabedian, Ph.D. Registration No. 39,197
Attorney for Applicant

## RESPONSE TO RESTRICTION REQUIREMENT

U.S. Patent and Trademark Office Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement mailed June 14, 2006, Applicant submits the following:

## Restriction Requirement

In the Restriction Requirement mailed June 14, 2006, the Examiner requested Applicant restrict the claims to one of the following groups of claims:

Group I, claims 1 - 28, drawn to a method of enhancing the immune response of a patient;

Group II, claim 29, drawn to an antibody which binds to a protein having an isoaspartic acid residue.

Applicant herein elects without traverse the claims of Group I, e.g., Claims 1-28, for prosecution on the merits.
Applicant reserves the right to file Divisional applications on the unelected claim group pursuant to 35 USC §§120 and 121.

## Species Election

The Examiner also imposed a Species Election and requested that the Applicant select one species from the following:

- (a) Cells or isolated proteins comprising tumor antigens containing an isoaspartic amino acid residue;
- (b) cells or isolated proteins comprising bacterial proteins containing an isoaspartic amino acid residue; and
- (c) cells or isolated proteins comprising viral proteins containing an isoaspartic amino acid residue.

In response to the species election, Applicant selects species (a) above, e.g., cells or isolated proteins comprising tumor antigens containing an isoaspartic amino acid residue.

Applicant submits that claims 1-5, 10-14, 17-22, and 25-29 read on the species selected above.

If the Examiner believes a telephone conference would aid in the continued prosecution of this application, the Examiner is invited and encouraged to contact Applicant's representative at the telephone number listed below.

Respectfully submitted,

MARK J. MAMULA

Todd E. Garabedian, Ph.D.

Registration No. 39,197
Attorney for Applicant

WIGGIN AND DANA LLP One Century Tower New Haven, CT 06508

Telephone: (203) 498-4400

Fax: (203) 782-2889

Date: 07 SEPT 2006